Navigation Links
Study Finds Both Coated Stents Perform the Same
Date:1/29/2008

Incidence of major adverse events was also lower than researchers anticipated

TUESDAY, Jan. 29 (HealthDay News) -- In a large study comparing the real-life effectiveness of two different drug-coated stents, Danish researchers found no overall difference between the two stents and a lower rate of problems than had been anticipated.

The scientists looked at more than 2,000 people who had these flexible tubes implanted to help keep arteries open, and the rate of major adverse events such as death, heart attack or blockage of the treated artery was about the same for stents coated with the drug paclitaxel, marketed by Boston Scientific, and those coated with sirolimus, marketed by Cordis. The report, funded by both stent makers, is published in the Jan. 30 issue of the Journal of the American Medical Association.

The study included people who underwent the artery-opening procedure called angioplasty, followed by stent implants, for a variety of conditions. It mostly involved patients who had had heart attacks, but it included some who had the disabling heart pain called angina. Previous, smaller studies have included a much narrower patient base.

"This is the first large-scale study to address the problem this way," said Dr. Kirk Garratt, clinical director of interventional cardiovascular research at Lenox Hill Hospital in New York City. "They excluded hardly anyone. And in a clinical practice that treats a broad spectrum of patients, it doesn't seem to matter much whether patients get the sirolimus-eluting stent or the paclitaxel-eluting stent."

The study did give a slight, but not statistically significant, edge to the sirolimus stent. The incidence of major adverse events was 9.3 percent for those getting that stent, compared to 11.2 percent for those getting the paclitaxel stent. Stent thrombosis rates were 2.5 percent for the sirolimus stent and 2.9 percent for the paclitaxel stent.

In a
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Pancreatic cancer: The smaller the tumor, the better your chances, study shows
2. Study Links Snoring to Chronic Bronchitis
3. Study finds genetic link to human herpes susceptibility
4. Researchers at Peoria Pulmonary Associates to study airway bypass procedure for emphysema
5. New study finds resistant organisms at core of soft contact lens corneal infections
6. Feds fund study of drug that may prevent radiation injury
7. Study examines self-expanding plastic stents in the treatment of benign esophageal conditions
8. Amalgam Fillings Dont Affect Childrens Brain Development, Says Study in ADA Journal
9. Amalgam fillings dont affect childrens brain development, says study in ADA Journal
10. Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds
11. From Research to Practice: Healthfitness, Eastman Chemical Company Case Study Demonstrates Real-World Health Gains and Productivity Savings
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Finds Both Coated Stents Perform the Same
(Date:6/2/2015)... Amercanex, the American Cannabis Exchange, today ... Amercanex’s new Chief Technology Officer. Amercanex is the ... wholesale distributors and retail vendors can buy, sell, ... intra-state market. , Jim Miller is an accomplished ... helping innovative technology companies deliver on their business ...
(Date:6/2/2015)... Date: Thursday, June 4, 2015 , Time: 2 ... Broad Street, 4th floor, Philadelphia, Pa 19107 , ... will visit Philadelphia City Council to urge city leaders ... C in Philadelphia’s at-risk populations. , Foundation leaders and ... B United Philadelphia (HBUP), will join Hepatitis C Allies ...
(Date:6/2/2015)... SB 277 (CA Legislature, bit.ly/1Q0P8OY) will require ... public or private school. SB277 cleared three Senate policy ... Committee (Sacramento Bee, May 11, 2015, bit.ly/1Gh9jU7). It passed ... “We believe that this bill affects the education of ... will (the) affect public health of California.. It is ...
(Date:6/1/2015)... City, NY (PRWEB) June 02, 2015 ... honors Lynn Lester as a 2015-2016 inductee ... is recognized with this prestigious distinction for leadership in ... for professional women, boasting more than 700,000 members and ... honor Lynn Lester with this prestigious award,” said NAPW ...
(Date:6/1/2015)... 2015 The National Association of ... 2015-2016 inductee into its VIP Woman of the ... distinction for leadership in business. NAPW is the ... boasting more than 700,000 members and over 200 ... Kathy into this exceptional group of professional women,” ...
Breaking Medicine News(10 mins):Health News:Amercanex Names Jim Miller to CTO Position 2Health News:Hepatitis B Foundation to Urge Philadelphia Leaders to Make Viral Hepatitis Prevention a Local Priority 2Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2Health News:National Association of Professional Women Inducts Lynn Lester, Director of Clinical Operations/CEO, Recovery Treatment Center, Into its VIP Woman of the Year Circle 2Health News:The National Association of Professional Women Inducts Kathy Everette-Gaines, Community Relations Coordinator, Into its VIP Professional Woman of the Year Circle 2
... , WASHINGTON , Feb. 17 ... his role in organizing a Detroit -area home health care ... the Criminal Division; U.S. Attorney for the Eastern District of Michigan ... the FBI,s Detroit Field Office; and Special Agent in Charge Lamont ...
... language paid attention to both, study found, , WEDNESDAY, ... languages spoken regularly during pregnancy might encourage babies to ... new study finds. , A team of psychological scientists ... Organization for Economic Cooperation and Development in France, watched ...
... the University of Cincinnati Neuroscience Institute (UCNI) at ... medication to prevent seizures in patients who have ... stroke. This randomized study supports earlier indications ... was as effective at preventing seizures as the ...
... Nurses who provide telephone advice services have to balance ... acting as a gatekeeper to limited healthcare services, according ... Journal of Advanced Nursing . Canadian ... two decades, covering more than 700 nurses in the ...
... ... in most specialties a unique cultural exchange at top-tier hospitals and medical facilities in the ... ... Staffing (GMS) announced that it has contracted with a group of top-tier hospitals and medical ...
... ... launched a new health education program to promote sound “mind and body” health practices ... ... National Alliance on Mental Illness ( NAMI ) has launched a new health education ...
Cached Medicine News:Health News:Home Health Agency Owner Pleads Guilty in Connection with Detroit Fraud Scheme 2Health News:Home Health Agency Owner Pleads Guilty in Connection with Detroit Fraud Scheme 3Health News:Bilingualism Might Begin in the Womb 2Health News:Study supports alternative anti-seizure medication following acute brain injury 2Health News:Study supports alternative anti-seizure medication following acute brain injury 3Health News:Study supports alternative anti-seizure medication following acute brain injury 4Health News:Telenurses face conflict between what is best for patients and what services are available 2Health News:Telenurses face conflict between what is best for patients and what services are available 3Health News:Global Medical Staffing Extends Locum Tenens Physician Placement to the Middle East 2Health News:“Hearts and Minds” Education Program Launched: On Average, People with Mental illness Live 25 Years Less than Other Americans, 2Health News:“Hearts and Minds” Education Program Launched: On Average, People with Mental illness Live 25 Years Less than Other Americans, 3Health News:“Hearts and Minds” Education Program Launched: On Average, People with Mental illness Live 25 Years Less than Other Americans, 4Health News:“Hearts and Minds” Education Program Launched: On Average, People with Mental illness Live 25 Years Less than Other Americans, 5
(Date:6/2/2015)... June 2, 2015 ... mejora  de 7,9 meses en la supervivencia libre ... con cáncer colorrectal metastático inoperable (mCRC) tratados  en ... Y-90 más quimioterapia    Los beneficios ... directamente al hígado con la quimioterapia sistémica actual ...
(Date:6/1/2015)... June 2, 2015 Amgen (NASDAQ: ... on a Phase 1b study to evaluate the ... oncolytic immunotherapy, in combination with Roche,s investigational anti-PDL1 ... with triple-negative breast cancer and colorectal cancer with ... investigational oncolytic immunotherapy designed to selectively replicate in ...
(Date:6/1/2015)... , June 1, 2015   Regulus Therapeutics ... company leading the discovery and development of innovative ... G. Xanthopoulos , Ph.D. has resigned as President ... of Regulus, Board of Directors, effective today, to ... Grint, M.D., who previously served as Chief Medical ...
Breaking Medicine Technology:Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 2Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 3Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 4Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 5Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 6Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 7Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 8Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 2Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 3Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 4Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 5Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 7Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 2Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 3Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 4
... IRVINE, Calif., June 12 Masimo (Nasdaq: ... Motion and Low-Perfusion pulse oximetry, announced today that three ... of Masimo PVI as a noninvasive and continuous measure ... week at the European Society of Anaesthesiology (ESA) Annual ...
... Safety and Biologic Activity Data Reviewed in End of Phase ... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a ... treatment of cardiovascular and metabolic disease, announced today that an ... VIA-2291 (atreleuton), was recently held with the U.S. Food and ...
Cached Medicine Technology:New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5
... a basic Peripheral Nerve Locator only, which ... location during regional anesthesia. Ideal for day ... constant current NS232, NS252, NS272 PNS are ... programmed. ,Hand-held, battery operated, and includes automatically ...
Pocket-size digital nerve locator optimizes ease and convenience of performing peripheral nerve blocks. Includes RBW-5L electrode lead set, 9V alkaline battery, and durable molded polyethylene carryi...
Single cuff electronic tourniquet....
The Lone Star Retractor System may be adapted to a specific region of the anatomy by simply adjusting the hinges. The system also includes multiple ring shapes, slots on perifephery of retractor ring...
Medicine Products: